Oligodendrogliomas: Clinical and genetic correlations

Current Opinion in Neurology

Volumn 14, Issue 6, 2001, Pages 705-710

  Perry, James R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; METHIONINE C 11; METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN SYNTHASE; PROTEIN P16; VASCULOTROPIN;

ANGIOGENESIS; BRAIN TUMOR; CARCINOGENESIS; DIAGNOSTIC PROCEDURE; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; MEDICAL GENETICS; NONHUMAN; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; GENETIC MARKERS; HUMANS; OLIGODENDROGLIOMA;

EID: 0035683959     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200112000-00005     Document Type: Review

References (32)

1. Current treatment of oligodendrogliomas
2. Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas
3. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
4. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
5. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis
6. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization
7. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
8. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas
9. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
10. Molecular genetic alterations in glioblastoma with oligodendroglial component
11. Chemosensitive gliomas in adults: Which ones and why?
12. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers
13. Oligodendrogliomas
14. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas
15. Non-invasive grading of oligodendrogliomas: Correlations between in vivo metabolic pattern and histopathology
16. Detection of 1p and 19 q loss in oligodendrogliomas by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay
17. Long-term survival of glioblastoma multiforme: Importance of histopathological reevaluation
18. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
19. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors
20. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy
21. Glutathione S-transferase and drug sensitivity in malignant glioma
22. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas
23. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis
24. Animal models of cell cycle dysregulation and the pathogensis of gliomas
25. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas
26. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398
27. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression
28. Vascular endothelial growth factor expression in oligodendrogliomas: A correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival
29. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas
30. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
31. Challenges in the design and conduct of phase III brain tumor therapy trials
32. Clinical trial end points in malignant glioma: Need for effective trial design strategy